F-18 PSMA Approval Status in India
The provided evidence does not contain any information regarding F-18 PSMA approval status specifically in India. The available guidelines and research focus exclusively on regulatory approvals in the United States, Europe, Australia, and other Western nations.
What the Evidence Shows About F-18 PSMA Approval Globally
The evidence demonstrates that F-18-labeled PSMA tracers have gained regulatory approval in several countries, but India is not mentioned in any of the provided documents:
United States FDA Approvals
- [18F]DCFPyL (piflufolastat F-18) received FDA approval in 2020 1, 2
- [18F]rhPSMA-7.3 also received FDA approval 2
- These approvals followed the initial 2020 FDA approval of [68Ga]Ga-PSMA-11 2
Clinical Use in Other Regions
The 2019 RADAR III guideline notes that "PSMA PET/CT shows great diagnostic potential but likely will not be available for widespread use in the United States for several years, although it being regularly used in some other nations (eg Australia, New Zealand, Germany and Brazil)" 3. India is notably absent from this list.
Key Limitation
None of the provided guidelines, drug labels, or research studies address regulatory approval status in India. The ASCO 2020 guideline 4 and RADAR III guideline 3 focus on Western healthcare systems and do not discuss Indian regulatory pathways or approvals.
What This Means Clinically
To determine whether F-18 PSMA tracers are approved in India, you would need to:
- Consult the Central Drugs Standard Control Organisation (CDSCO) in India
- Check with the Atomic Energy Regulatory Board (AERB) for radiopharmaceutical approvals
- Contact local nuclear medicine departments or professional societies in India
The evidence provided cannot answer your question about Indian regulatory approval status.